ACVR1

(redirected from TSRI)
Also found in: Acronyms.

ACVR1

A gene on chromosome 2q23-q24 that encodes activin receptor type I, a receptor that forms a complex with other type-I and two type-II transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. Type-II receptors phosphorylate and activate type-I receptors, which autophosphorylate, then bind and activate SMAD transcriptional regulators, playing roles in cell differentiation, growth arrest and apoptosis. 

Molecular pathology
ACVR1 mutations are linked to fibrodysplasia ossificans progressive.
References in periodicals archive ?
TSRI will provide "significant resources" including the transplantation expertise of its scientists.
Jones, Chih-Wei Lin, Walter Francesconi, Fulvia Berton, Mohammad Fallahi, and Karsten Sauer, all of TSRI during the study.
I am delighted that Pete and Steve will assume leadership roles at TSRI," said Dick Gephardt, Chair of the TSRI Board of Trustees and President/CEO of Gephardt Government Affairs.
Scientists at TSRI studied the structure of the immunogen at every point in the process.
The results are pretty spectacular," said Dennis Burton, chair of the TSRI Department of Immunology and Microbial Science and scientific director of two centers at TSRI, the IAVI Neutralizing Antibody Consortium (NAC) and the National Institutes of Health (NIH) Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID).
We were inspired by this unique structure found in nature, and we assembled an antibody that might one day benefit humans," said TSRI Research Associate Tao Liu, co-first author of the new study with Yong Zhang at Calibr.
We hope to ultimately increase scientists' ability to target any disease," said Art Olson, professor and Anderson Research Chair at TSRI who is senior author of the new study.
he continued research at TSRI for two more years and in 2003 returned to Sweden and Stockholm University.
The authors, who include NAC and other TSRI scientists, are in the process of preparing additional papers from this research.
Wilson, the Hansen Professor of Structural Biology and chair of the Department of Integrative Structural and Computational Biology at TSRI, said.
Maximum payout for the TSRIs, which will also be substantially lower than in previous plans, will occur only if Occidental's cumulative 3-year TSRI performance ranks 1st among its 12 peer companies and outperforms the S&P 500.
An analyst report on TSRI that includes a company overview, market and competition breakdown, recent events, outlook, analyst summary, valuation, and recommendation can be viewed by using the following link at no cost: